Argireline (Acetyl Hexapeptide-8)

Argireline (Acetyl Hexapeptide-8) at a Glance

Argireline is acetyl hexapeptide-8, a synthetic peptide designed to mimic the SNAP-25 protein that neurons use to release acetylcholine at the neuromuscular junction. By competing with SNAP-25 it is intended to soften muscle contraction in expression lines — the same target botulinum toxin acts on, which is why it is marketed as a topical Botox alternative. It is a cosmetic ingredient rather than a drug, and the central question for any topical peptide applies: whether a molecule this size crosses the stratum corneum in meaningful quantity.

History & Development

Argireline was designed to do what Botox does, without the needle - by copying the piece of protein that botulinum toxin attacks.

First described	Not established in the sources consulted for this section
Discovered / synthesised by	Developed by Lipotec
Institution	Lipotec
Origin	Synthetic six-residue peptide, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2 (Ac-EEMQRR-NH2, MW ~889 Da); mimics the N-terminal of SNAP-25
Key patent	Not established in the sources consulted for this section
Assignee	Lipotec
Development status	Cosmetic ingredient - INCI acetyl hexapeptide-8; not an approved drug in any jurisdiction

Discovery

Muscle contraction needs neurotransmitter release, and that release needs the SNARE complex - proteins that dock a vesicle to the cell membrane. SNAP-25 is one of them, and it is the protein botulinum toxin cleaves. No SNAP-25, no vesicle fusion, no contraction.

Argireline is a six-residue peptide mimicking the N-terminal end of SNAP-25. The idea is competitive: a decoy fragment that occupies the SNARE assembly and destabilises it, so vesicle fusion becomes less efficient and expression lines soften. The mechanism is genuinely elegant, and it is why the compound is marketed as topical Botox.

The mechanism and the delivery are separate questions, and it is the second one that decides whether a topical peptide can reach a facial muscle at all.

Development & ownership

Argireline is a trade name; the ingredient’s regulatory identity is acetyl hexapeptide-8, also sold as acetyl hexapeptide-3. It was developed by Lipotec, and it became one of the most widely adopted cosmetic peptides in the industry - it appears in an enormous range of products, usually at low percentages.

Its longer relative SNAP-8, acetyl octapeptide-3, extends the same sequence by two residues on the same rationale.

How it reached the market

As a cosmetic ingredient, argireline needed no pre-market approval. Cosmetics are regulated on safety and labelling rather than efficacy in the US and EU, so a topical anti-wrinkle claim does not require the evidence a drug claim would. That is the regulatory reason a mechanism this specific can be sold this widely on evidence this thin.

What It's Used For

Argireline is the trade name for acetyl hexapeptide-8 (also sold as acetyl hexapeptide-3; sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂ / Ac-EEMQRR-NH₂, MW ≈ 889 Da), a synthetic six-residue peptide developed by Lipotec (now Lubrizol) and rationally designed to mimic the N-terminal end of SNAP-25 — the SNARE protein that botulinum toxin cleaves. Hence the marketing: “Botox in a bottle.” Unlike the injectable research peptides elsewhere on this hub, Argireline is a leave-on topical cosmetic ingredient, and route is the whole story. For the advertised mechanism to operate, an ~889 Da hydrophilic, zwitterionic peptide would have to cross intact stratum corneum, traverse the epidermis and dermis, and reach a motor nerve terminal — and the conventional dermatological rule of thumb is that molecules above ~500 Da do not meaningfully cross intact skin at all. The best quantitative data say it largely does not: an in-vitro diffusion-cell study by US FDA cosmetics-toxicology researchers, applying a 10% oil-in-water emulsion to human cadaver and hairless-guinea-pig skin, recovered most of the dose from the surface wash, found the peptide mostly stranded in the (dead) stratum corneum, and measured only about 0.01% reaching the viable epidermis and none in the dermis or receptor fluid ^{7Reference 7Kraeling ME et al. · 2015In vitroIn vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation — FDA researchers; human cadaver and hairless-guinea-pig skin diffusion cells — in vitroView study →}.

Meanwhile the independent Cosmetic Ingredient Review Expert Panel (2025) could conclude safety only up to 0.005% — a thousandfold below the 5–10% used to generate the efficacy data ^{11Reference 11Johnson W Jr et al. · 2025ReviewSafety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics — CIR Expert Panel; safe up to 0.005%, data insufficient above — expert-panel safety reviewView study →}.

So the mechanism is real in a test tube, the delivery to its target is not demonstrated, and the two published concentration regimes (what works, what is cleared as safe) barely overlap.

A second problem is who generated the evidence. Argireline is a commercial cosmetic ingredient, and a large share of its “literature” is manufacturer-sourced: supplier technical dossiers, in-house efficacy testing, marketing white papers and small uncontrolled studies in cosmetic-industry journals. Of the human work indexed on PubMed, the origin paper is authored by the developer’s own team ^{1Reference 1Blanes-Mira C et al. · 2002In vitroA synthetic hexapeptide (Argireline) with antiwrinkle activity — developer-authored cosmetic efficacy study + mechanism — human (open-label, manufacturer-associated) and in vitroView study →}, and the most-quoted efficacy dataset (n=60, Chinese subjects) was published three separate times by the same group ^{2,3,4Reference 2Wang Y et al. · 2013RCTThe anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study — human (RCT, n=60)View study →Reference 3Wang Y et al. · 2013RCTThe anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects — same n=60 clinical dataset as [2] plus the aged-mouse arm — human (RCT) + animal (mouse)View study →Reference 4Wang Y et al. · 2013AnimalThe anti-wrinkle efficacy of Argireline — the aged-mouse (D-galactose) histology arm reported separately; same dataset as [3] — animal (mouse)View study →} — one dataset that reads at a glance like three studies. Genuinely independent, isolated-peptide human evidence amounts to roughly two small trials: the Wang n=60 randomized placebo-controlled wrinkle study ^{2Reference 2Wang Y et al. · 2013RCTThe anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study — human (RCT, n=60)View study →} and a four-arm n=24 study with an isolated acetyl-hexapeptide-3 group of about six people ^{5Reference 5Raikou V et al. · 2017RCTThe efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3 — four-arm randomised study, n=24 total (≈6 per arm), includes an isolated acetyl-hexapeptide-3 arm — human (RCT)View study →}.

The single most rigorous, most independent test of the compound was not cosmetic at all — an NIH/NINDS double-blind randomized trial in blepharospasm — and it missed its primary endpoint ^{6Reference 6Lungu C et al. · 2013RCTPilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy — primary endpoint not met — human (double-blind RCT, n=24; NCT00942851)View study →}.

Manufacturer data is not worthless, but an unblinded supplier study is not an RCT, and the provenance of every claim is labelled.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up.

Read the blepharospasm row carefully. Its score is low because the compound was tested and the primary endpoint was not met, not because nobody looked. That is a different and more informative kind of low score than “never studied.” Note also that the wrinkle row’s apparent study count is inflated by one dataset published three times, and that the un-scored rows below are un-scored because their only support is manufacturer marketing.

01Facial wrinkle reduction (periorbital / expression lines)Promising45%One placebo-controlled human RCT (n=60, triple-published), the developer’s own origin study, one isolated arm of an n=24 four-arm study, plus a completed Phase 3 that never posted results. Subjective + surface-topography endpoints, no EMG, penetration unresolved.

02Blepharospasm (topical adjunct to botulinum toxin)Shaky20%One NIH double-blind RCT (n=24) — primary endpoint not met, non-significant trend only; Phase 2 follow-on terminated at n=8. Scored low for a negative result, not absence of data.

03Skin hydration / barrier (TEWL)Shaky20%A single secondary endpoint in one four-arm study (isolated-peptide arm ≈6 subjects) ^{5Reference 5Raikou V et al. · 2017RCTThe efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3 — four-arm randomised study, n=24 total (≈6 per arm), includes an isolated acetyl-hexapeptide-3 arm — human (RCT)View study →}, plus a zebrafish-embryo model.

04Skin firmness / collagen remodelingShaky15%Aged-mouse histology only (one dataset, reported twice), plus an ex-vivo study of a five-active serum in which the peptide cannot be isolated. No human isolated-peptide dermal evidence.

Mechanisms

Pharmacokinetics

Route: topical, leave-on cosmetic. Argireline is applied to intact skin in creams and serums, at single-digit to ~10% peptide-solution concentrations in the efficacy literature. It is neither an oral nor an injectable product, and its defining pharmacokinetic fact is that it barely gets in. At ~889 Da it sits well above the ~500 Da rule of thumb for percutaneous absorption, and it is hydrophilic and zwitterionic — poorly suited to diffusing through a lipophilic, protein-crosslinked stratum corneum, and vulnerable to skin proteases en route ^{8,9Reference 8Lim SH et al. · 2018In vitroEnhanced skin permeation of anti-wrinkle peptides via molecular modification — in vitroView study →Reference 9Zdrada-Nowak J et al. · 2025ReviewAcetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy — reviewView study →}. The quantitative measurement comes from an in-vitro diffusion-cell study by FDA cosmetics-toxicology researchers: a 10% oil-in-water emulsion dosed at 2 mg/cm² on human cadaver and hairless-guinea-pig skin for 24 hours, with LC-MS/MS quantification against stable-isotope-labeled internal standards. Most of the applied peptide washed off the surface; what remained was concentrated in the stratum corneum (~0.22% of dose in human skin), with only about 0.01% reaching the viable epidermis and none detectable in dermis or receptor fluid — and the deacetylated metabolite was not detected at all ^{7Reference 7Kraeling ME et al. · 2015In vitroIn vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation — FDA researchers; human cadaver and hairless-guinea-pig skin diffusion cells — in vitroView study →}. The stratum corneum is dead tissue; peptide sitting in it is not peptide at a nerve terminal.

Because so little is absorbed, there is no meaningful systemic pharmacokinetics and no established half-life for topical use. That cuts both ways: it is the main reason systemic toxicity and drug interactions are considered unlikely, and simultaneously the main reason the advertised mechanism is doubtful. Delivery enhancement is consequently the active research front — molecular modification to suppress zwitterion formation ^{8Reference 8Lim SH et al. · 2018In vitroEnhanced skin permeation of anti-wrinkle peptides via molecular modification — in vitroView study →}, oil-in-water and water-in-oil-in-water emulsions, propylene-glycol co-solvents, liposomal and encapsulated vehicles, iontophoresis, and microneedle patches ^{8,9Reference 8Lim SH et al. · 2018In vitroEnhanced skin permeation of anti-wrinkle peptides via molecular modification — in vitroView study →Reference 9Zdrada-Nowak J et al. · 2025ReviewAcetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy — reviewView study →}. Some of these raise permeation substantially in vitro; none has yet demonstrated delivery to human dermis or to a neuromuscular junction in vivo, which is the measurement that would actually settle the question. Note that vehicle matters enormously here, so a permeation figure from one formulation does not transfer to another product. Stability: the methionine residue oxidizes readily, and oxidized Argireline has been detected in marketed cosmetics — a real-world formulation and QC concern independent of the delivery problem ^{14Reference 14Kluczyk A et al. · 2021In vitroArgireline: Needle-Free Botox as Analytical Challenge — methionine oxidation and stability in marketed cosmetics — analytical / in vitroView study →}.

Clinical & regulatory status

Argireline / acetyl hexapeptide-8 is a cosmetic ingredient, not an approved drug in any jurisdiction, and not an approved dietary supplement. It carries an INCI name and is sold as a leave-on cosmetic active; cosmetics receive no FDA or EMA pre-market approval, and a genuine “relaxes facial muscles” claim would be a drug claim the ingredient is not licensed to make. The independent Cosmetic Ingredient Review Expert Panel published a safety assessment in 2025 concluding the ingredient is safe in cosmetics at concentrations up to 0.005%, and explicitly that the available data were insufficient to conclude safety above that ^{11Reference 11Johnson W Jr et al. · 2025ReviewSafety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics — CIR Expert Panel; safe up to 0.005%, data insufficient above — expert-panel safety reviewView study →} — which is roughly a thousand to two thousand times below the 5–10% used in the efficacy studies.

Registered human-trial activity is modest and, notably, mostly not manufacturer-run: six registered studies (five completed, one terminated, none ongoing), sponsored by Mahidol University, NINDS, UC Davis, Wayne State and a cosmetics brand. Five of the six have posted no results. They are: the Phase 3 periorbital-wrinkle study (NCT01381484, n=70, completed 2009, no results); two blepharospasm trials (NCT00942851, Phase 1/2, n=24, completed with results posted — see application 2; NCT01750346, Phase 2, terminated at n=8, results posted); an oily-skin/sebum study (NCT02597777, n=14, completed 2016, no results); and two multi-ingredient cosmetic-formula trials in which the peptide is one active among several — a compounded-cream wrinkle study (NCT03878381, Early Phase 1, n=10, no results) and a branded eye-serum study (NCT06143033, n=35, no results). The last two isolate no peptide-specific effect and are counted below but carry no weight as isolated-peptide evidence. No approval for any therapeutic indication exists or is being pursued.

Last checked: July 2026.

Sourcing, Route & Legal Status

Regulatory status. Argireline is a legal, widely sold cosmetic ingredient — this is not a gray-market research chemical in the sense that the injectable peptides on this hub are, and the sourcing risks are correspondingly different. It has an INCI name, appears in cosmetic ingredient inventories worldwide, and is present in a large number of ordinary retail skincare products. What it is not is an approved drug or supplement: cosmetics are not pre-market approved, so no regulator has evaluated any efficacy claim made for it, and the marketing language (“needle-free Botox”, “up to 30% wrinkle reduction”) is unverified by any authority. The independent CIR panel’s 2025 conclusion — safe up to 0.005%, data insufficient above that — is the closest thing to an official safety position ^{11Reference 11Johnson W Jr et al. · 2025ReviewSafety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics — CIR Expert Panel; safe up to 0.005%, data insufficient above — expert-panel safety reviewView study →}.

The practically useful fact for a buyer. Because cosmetics are not regulated as drugs, the concentration is usually undisclosed. Argireline appears on an ingredient list by name, in descending-concentration order at best, with no percentage attached. The efficacy studies used 5–10% peptide solution; a great many finished consumer products contain far less — sometimes fractions of a percent, sometimes enough only to justify the name on the label. There is no way to tell from the packaging. So the honest position is: even if you accept the (modest, small-study, partly industry-sourced) efficacy data at face value, you have no way of knowing whether the product in your hand contains anything like the tested concentration. Products advertising “10% Argireline” are typically quoting 10% of the supplied peptide solution, which itself is a dilute aqueous solution of the peptide — not 10% peptide. That distinction is rarely made clear.

How it’s supplied & administered. As a finished cosmetic it is a leave-on cream or serum applied to intact skin, usually twice daily in the studies. It is also sold as raw lyophilized powder or aqueous solution to home formulators and DIY skincare makers. The intended and only validated route is topical.

Route misuse is the one real safety issue. Some users have injected Argireline in pursuit of a cheap botulinum-toxin substitute. This is misuse of a non-sterile cosmetic material: it is not manufactured, purified, or packaged as a sterile injectable, and a published case report describes disfiguring Mycobacterium abscessus facial abscesses following injection, requiring five months of antibiotic treatment ^{12Reference 12Chen CF et al. · 2021Case reportMycobacterium abscessus infection after facial injection of argireline: a case report — human (single case report; injection is misuse)View study →}. There is no efficacy rationale for injecting it either — the in-vitro efficacy against neurotransmitter release is far below botulinum toxin’s, so injecting does not convert it into a botulinum equivalent. For raw powder bought from unregulated suppliers, purity, actual peptide content, oxidation state and endotoxin load are unverified without third-party certificates of analysis; methionine oxidation is documented even in finished retail products ^{14Reference 14Kluczyk A et al. · 2021In vitroArgireline: Needle-Free Botox as Analytical Challenge — methionine oxidation and stability in marketed cosmetics — analytical / in vitroView study →}. This page does not recommend or link vendors.

Safety

As a leave-on topical, Argireline looks benign — but the concentrations that produced the efficacy data sit about a thousandfold above the concentration anyone has formally cleared as safe, and the one documented serious harm came from injecting it.

Safety at a Glance

❔ Toxicity unknownAllergy risk

• Well tolerated as a leave-on topical. The human trials reported no significant adverse events over weeks of daily application, and systemic exposure is negligible.
• Never inject it. This is a non-sterile cosmetic, and facial injection has caused disfiguring mycobacterial infection.
• Assessed safe only up to 0.005%. The independent CIR panel found data insufficient above that — well below the 5–10% used in the efficacy studies.
• Local reactions are the expected effect. Application-site irritation, redness or contact sensitization.
• Interactions not studied. Negligible absorption makes systemic interaction unlikely, but it is untested.
• Storage and formulation matter. Methionine-oxidation products in poorly formulated or badly stored goods are an unquantified exposure.

Full Safety & Interactions Detail

Argireline is reported as well tolerated as a leave-on topical cosmetic, which is the only use with any safety basis at all. The human trials — the placebo-controlled wrinkle study and the blepharospasm RCT — reported it as safe and well tolerated with no significant adverse events over weeks of daily topical application ^{2,6Reference 2Wang Y et al. · 2013RCTThe anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study — human (RCT, n=60)View study →Reference 6Lungu C et al. · 2013RCTPilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy — primary endpoint not met — human (double-blind RCT, n=24; NCT00942851)View study →}, and systemic exposure is negligible precisely because so little penetrates ^{7Reference 7Kraeling ME et al. · 2015In vitroIn vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation — FDA researchers; human cadaver and hairless-guinea-pig skin diffusion cells — in vitroView study →}.

In-vitro cytotoxicity appeared only at concentrations 18- to 10,000-fold above those at which the reference cytotoxin doxorubicin acts, i.e. far above cosmetic use levels ^{13Reference 13Grosicki M et al. · 2014In vitroThe study of cellular cytotoxicity of argireline — an anti-aging peptide — in vitroView study →}.

Set against this, the independent CIR panel could clear cosmetic use only up to 0.005% and found data insufficient above that ^{11Reference 11Johnson W Jr et al. · 2025ReviewSafety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics — CIR Expert Panel; safe up to 0.005%, data insufficient above — expert-panel safety reviewView study →} — so the concentrations at which efficacy was demonstrated are outside the range that has been formally assessed as safe. That is a gap in assessment, not a demonstration of harm, and it should be read as such.

The expected adverse effects for any leave-on peptide active are local: application-site irritation, redness, or contact sensitization. Methionine-oxidation products in poorly formulated or badly stored goods are an unquantified exposure ^{14Reference 14Kluczyk A et al. · 2021In vitroArgireline: Needle-Free Botox as Analytical Challenge — methionine oxidation and stability in marketed cosmetics — analytical / in vitroView study →}.

Interactions have not been studied — there is no controlled interaction data, and negligible systemic absorption makes systemic interaction unlikely but untested. The dominant real-world harm on record is not toxicity of the molecule but misuse of route: injecting this non-sterile cosmetic has caused serious mycobacterial infection ^{12Reference 12Chen CF et al. · 2021Case reportMycobacterium abscessus infection after facial injection of argireline: a case report — human (single case report; injection is misuse)View study →}.

Do not inject it.

Scope disclosure (what has and hasn’t been assessed):

• Human data? Yes, but small and mostly cosmetic-grade — one placebo-controlled wrinkle RCT (n=60, published three times), the developer’s own origin study, one ~6-per-arm isolated-peptide arm, a completed Phase 3 with no posted results, and one independent medical RCT whose primary endpoint was not met.
• Independent vs manufacturer-sourced? Mixed, and often manufacturer-sourced — the origin study is the developer’s; the registered trials are mostly academic; a large volume of quoted “evidence” is supplier dossier and marketing material that is not cited anywhere.
• Delivery to target demonstrated? No — ~0.01% to viable epidermis, none to dermis in vitro ^{7Reference 7Kraeling ME et al. · 2015In vitroIn vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation — FDA researchers; human cadaver and hairless-guinea-pig skin diffusion cells — in vitroView study →}; no in-vivo human evidence that the peptide reaches a neuromuscular junction.
• Interactions assessed? No — no controlled studies; negligible absorption makes systemic interaction unlikely but untested.
• Pregnancy/lactation assessed? No — not established.
• Long-term safety established? No — trials run weeks, not years; no long-term topical data, and no safety data whatsoever for any injected use (which is misuse and has caused infection).

Never imply safety from silence. “Well tolerated” here reflects small short-term cosmetic studies and an expert-panel review capped at 0.005% — not an assessment of the concentrations actually used to claim efficacy.

Pregnancy & Lactation

? Not established in pregnancy? Not established in lactation

Not assessed / not established. No pregnancy or lactation safety data exist for topical Argireline, and the CIR assessment does not establish safety in these groups. Systemic absorption is expected to be negligible, but that is an absence of study, not a demonstration of safety — treat as unknown.

Dosage

There is no established human dose for Argireline, and none is recommended here. It is a topical cosmetic ingredient, not a dietary supplement or drug, so there is no oral or injectable dose — and it must not be injected under any circumstances ^{12Reference 12Chen CF et al. · 2021Case reportMycobacterium abscessus infection after facial injection of argireline: a case report — human (single case report; injection is misuse)View study →}.

For context only: the efficacy studies applied 5–10% peptide solution topically, twice daily, to periorbital skin over 4–8 weeks ^{1,2,5Reference 1Blanes-Mira C et al. · 2002In vitroA synthetic hexapeptide (Argireline) with antiwrinkle activity — developer-authored cosmetic efficacy study + mechanism — human (open-label, manufacturer-associated) and in vitroView study →Reference 2Wang Y et al. · 2013RCTThe anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study — human (RCT, n=60)View study →Reference 5Raikou V et al. · 2017RCTThe efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3 — four-arm randomised study, n=24 total (≈6 per arm), includes an isolated acetyl-hexapeptide-3 arm — human (RCT)View study →}. The independent CIR Expert Panel concluded cosmetic use is safe only up to 0.005%, with data insufficient above that ^{11Reference 11Johnson W Jr et al. · 2025ReviewSafety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics — CIR Expert Panel; safe up to 0.005%, data insufficient above — expert-panel safety reviewView study →}. Those two numbers differ by roughly a thousandfold and cannot be reconciled — the practical consequence is that a product using the studied concentration exceeds the assessed-safe concentration, and a product staying within the assessed-safe concentration is nowhere near the studied one. Since finished cosmetics rarely disclose concentration at all, most consumers are in neither category knowingly. This is formulation practice and regulatory record, not a clinically validated dose, and this is informational only.

References

1. Blanes-Mira C, et al. (2002). A synthetic hexapeptide (Argireline) with antiwrinkle activity — developer-authored cosmetic efficacy study + mechanism — human (open-label, manufacturer-associated) and in vitro. International Journal of Cosmetic Science. https://pubmed.ncbi.nlm.nih.gov/18498523/
2. Wang Y, et al. (2013). The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study — human (RCT, n=60). American Journal of Clinical Dermatology. https://pubmed.ncbi.nlm.nih.gov/23417317/
3. Wang Y, et al. (2013). The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects — same n=60 clinical dataset as [2] plus the aged-mouse arm — human (RCT) + animal (mouse). Journal of Cosmetic and Laser Therapy. https://pubmed.ncbi.nlm.nih.gov/23607739/
4. Wang Y, et al. (2013). The anti-wrinkle efficacy of Argireline — the aged-mouse (D-galactose) histology arm reported separately; same dataset as [3] — animal (mouse). Journal of Cosmetic and Laser Therapy. https://pubmed.ncbi.nlm.nih.gov/23464592/
5. Raikou V, et al. (2017). The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3 — four-arm randomised study, n=24 total (≈6 per arm), includes an isolated acetyl-hexapeptide-3 arm — human (RCT). Journal of Cosmetic Dermatology. https://pubmed.ncbi.nlm.nih.gov/28150423/
6. Lungu C, et al. (2013). Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy — primary endpoint not met — human (double-blind RCT, n=24; NCT00942851). European Journal of Neurology. https://pubmed.ncbi.nlm.nih.gov/23146065/
7. Kraeling ME, et al. (2015). In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation — FDA researchers; human cadaver and hairless-guinea-pig skin diffusion cells — in vitro. Cutaneous and Ocular Toxicology. https://pubmed.ncbi.nlm.nih.gov/24754410/
8. Lim SH, et al. (2018). Enhanced skin permeation of anti-wrinkle peptides via molecular modification — in vitro. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/29371611/
9. Zdrada-Nowak J, et al. (2025). Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy — review. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/40565185/
10. Lum K, et al. (2025). Acetyl Hexapeptide-8 as a Topical Alternative to Botulinum Toxin: A Review of the Literature — review. Journal of Drugs in Dermatology. https://pubmed.ncbi.nlm.nih.gov/40196949/
11. Johnson W Jr, et al. (2025). Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics — CIR Expert Panel; safe up to 0.005%, data insufficient above — expert-panel safety review. International Journal of Toxicology. https://pubmed.ncbi.nlm.nih.gov/40673537/
12. Chen CF, et al. (2021). Mycobacterium abscessus infection after facial injection of argireline: a case report — human (single case report; injection is misuse). World Journal of Clinical Cases. https://pubmed.ncbi.nlm.nih.gov/33748252/
13. Grosicki M, et al. (2014). The study of cellular cytotoxicity of argireline — an anti-aging peptide — in vitro. Acta Biochimica Polonica. https://pubmed.ncbi.nlm.nih.gov/24644551/
14. Kluczyk A, et al. (2021). Argireline: Needle-Free Botox as Analytical Challenge — methionine oxidation and stability in marketed cosmetics — analytical / in vitro. Chemistry & Biodiversity. https://pubmed.ncbi.nlm.nih.gov/33482052/
15. Jiang X, et al. (2025). BAK and ARG have moisturizing, anti-inflammatory and antioxidant bioactivities in the zebrafish model — animal (zebrafish embryo). Journal of Cosmetic Dermatology. https://pubmed.ncbi.nlm.nih.gov/40176351/
16. Zhu M, et al. (2026). The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and texture — multi-ingredient formula; peptide not isolated — ex vivo human skin + human (clinical). International Journal of Cosmetic Science. https://pubmed.ncbi.nlm.nih.gov/41668671/

View all 16 references▾